BUSINESS WIRE; Tuesday, May 26, 1998
This announcement follows a trip to Romania and the establishment of a Romanian subsidiary of STGI by Alfred T. Sapse, M.D., the company's founder and president.
Cortisol is a powerful hormone manufactured by the adrenal gland during times of stress. A growing body of scientific data confirms that prolonged high levels of cortisol can destroy the immune system and play a major role in AIDS, several forms of cancer and many diseases associated with old age.
ANTICORT is designed to counteract cortisol's immunosuppressive effect through an anti-cortisol action that improves the quality of the immune system. Preliminary clinical results submitted to AIDS World Conferences (Vancouver 1996, Marrakech 1995) serve to confirm ANTICORT's effectiveness.
In the United States, STGI has received FDA approval to commence a Phase Ib/Iia clinical study of ANTICORT for treating an HIV-positive adult population. A clinical study testing the effectiveness of the ANTICORT Infacap on 40 HIV-positive children is scheduled to begin in early September 1998, following Romanian regulatory approval. The study could be completed by April 1999.
Steroidogenesis Inhibitors International is a leader in the emerging cortisol/anti-cortisol pharmaceutical industry. The company has headquarters at 2001 E. Flamingo Blvd., Suite 100B, Las Vegas, Nev. 89119; telephone 702/735-7001; fax 702/737-7016; www.cortisol.com.
Statements in this news release relating to matters that are not historical facts are forward-looking statements. Such statements are based on the company's current forecasts and actual results may differ materially. For additional information regarding STGI, contact Janet Greeson, Ph.D., investor relations, 800/663-1992.
Contact: Steroidogenesis Inhibitors International STGI Investor Relations Janet Greeson, 800/663-1992 or Tellem Inc. Erik Deutsch, 213/935-1725 or 818/410-4540 (pager)
980526
BW980510
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .